Increased cell proliferation activity and decreased cell death are associated with the emergence of hormone-refractory recurrent prostate cancer

Journal of Pathology

Volumn 183, Issue 1, 1997, Pages 51-56

  Koivisto, Pasi ^a,b   Visakorpi, Tapio ^a   Rantala, Immo ^b   Isola, Jorma ^a  

^a UNIVERSITY OF TAMPERE   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Androgen receptor gene; Cell kinetics; Hormonal therapy; Hormone refractory; Ki 67; Programmed cell death

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; DNA FRAGMENT; KI 67 ANTIGEN;

APOPTOSIS; ARTICLE; CANCER HORMONE THERAPY; CANCER RECURRENCE; CELL DEATH; CELL KINETICS; CELL PROLIFERATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; CELL DIVISION; DISEASE PROGRESSION; HUMANS; KI-67 ANTIGEN; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROSTATIC NEOPLASMS; TREATMENT FAILURE;

EID: 0030879959     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199709)183:1<51::AID-PATH1092>3.0.CO;2-N     Document Type: Article

References (36)

1. Huggins C, Hodges CV. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-297.
2. Gittes RF. Carcinoma of the prostate. N Engl J Med 1991; 324: 235-245.
3. Stearns ME, McGarvey T. Biology of the disease. Prostate cancer: therapeutic, diagnostic, and basic studies. Lab Invest 1992; 67: 540-552.
4. Visakorpi T, Kallioniemi O-P, Koivula T, Isola J. New prognostic factors in prostatic carcinoma. Eur Urol 1993; 24: 438-449.
5. Isaacs JT, Lundmo PI, Berges R, Martikainen P, Kyprianou N, English HF. Androgen regulation of programmed death of normal and malignant prostatic cells. J Androl 1992; 13: 457-464.
6. Westin P, Stattin P, Damber J-E, Bergh A. Castration therapy induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am J Pathol 1995; 146: 1368-1375.
7. Kerr JFR, Searle J. Deletion of cells by apoptosis during castration-induced involution of rat prostate. Virchows Arch B / Cell Pathol J 1973; 13: 87-102.
8. Sandford NL, Searle JW, Kerr JFR. Successive waves of apoptosis in the rat prostate after repeated withdrawal of testosterone stimulation. Pathology 1984; 16: 406-410.
9. Kyprianou N, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 1990; 50: 3748-3753.
10. Berges RR, Vukanovic J, Epstein JI, et al. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1995; 1: 473-480.
11. van Werden WM, van Kreuningen A, Elissen NMJ, et al. Castration-induced changes in morphology, androgen levels, and proliferative activity of human prostate cancer tissue grown in athymic nude mice. Prostate 1993; 23: 149-164.
12. UICC. TNM. Classification of Malignant Tumours. 4th edn. Berlin: Springer-Verlag, 1987.
13. Mostofi FK. Histological Typing of Prostate Tumours. Geneva: World Health Organization, 1980.
14. Hall PA, Woods AL. Immunohistochemical markers of cellular proliferation: achievements, problems and prospects. Cell Tissue Kinet 1990; 23: 505-522.
15. Isola JJ, Helin HJ, Helle MJ, Kallioniemi O-P. Evaluation of cell proliferation in breast carcinoma. Comparison of Ki-67 immunohistochemical study, DNA flow cytometric analysis, and mitotic count. Cancer 1990; 65: 1180-1184.
16. Dawson AE, Norton JA, Weinberg DS. Comparative assessment of proliferation and DNA content in breast carcinoma by image analysis and flow cytometry. Am J Pathol 1990; 136: 1115-1124.
17. Sasaki K, Matsumura K, Tsuji T, Shinozaki F, Takahashi M. Relationship between labelling indices of Ki-67 and BrdUrd in human malignant tumors. Cancer 1988; 62: 989-993.
18. Cher ML, Chew K, Rosenau W, Carroll PR. Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression. Prostate 1995; 26: 87-93.
19. Banerjee PP, Banerjee S, Tilly KI, Tilly JL, Brown TR, Zirkin BR. Lobe-specific apoptotic cell death in rat prostate after androgen ablation by castration. Endocrinology 1995; 136: 4368-4376.
20. Gallee MPW, Visser de Jong E, Ten Kate FJW, Schöder FH, van der Kwast TH. Monoclonal antibody Ki-67 defined growth fraction in benign prostatic hyperplasia and prostatic cancer. J Urol 1989; 142: 1342-1346.
21. McLoughlin J, Foster CS, Price P, Williams G, Abel PD. Evaluation of Ki-67 monoclonal antibody as prognostic indicator for prostatic carcinoma. Br J Urol 1993; 72: 92-97.
22. Aihara M, Scardino PT, Truong LD, et al. The frequency of apoptosis correlates with the prognosis of Gleason grade 3 adenocarcinoma of the prostate. Cancer 1995; 75: 522-529.
23. Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancers. Nature Genet 1995; 9: 401-406.
24. Koivisto P, Kononen J, Palmberg C, et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997; 57: 314-319.
25. Newmark JR, Hardy DO, Tonb DC, et al. Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci USA 1992; 89: 6319-6323.
26. Culig Z, Hobisch A, Cronauer MV, et al. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 1993; 7: 1541-1550.
27. Suzuki H, Sato N, Watabe Y, Masai M, Seino S, Shimazaki J. Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 1993; 46: 759-765.
28. Gaddipati JP, McLeod DG, Heidenberg HB, et al. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancer. Cancer Res 1994; 54: 2861-2864.
29. Ruizeveld de Winter JA, Janssen PJ, Sleddens HM, et al. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Palhol 1994; 144: 735-746.
30. 24→18) in the androgen receptor gene in human prostate cancer. Biochem Biophys Res Commun 1994; 198: 74-80.
31. Vukanovic J, Isaacs JT. Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide. Cancer Res 1995; 55: 3517-3520.
32. Aihara M, Truong LD, Dunn JK, Wheeler TM, Scardino PT, Thompson TC. Frequency of apoptotic bodies positively correlates with Gleason grade in prostate cancer. Hum Pathol 1994; 25: 797-801.
33. Colombel M, Symmans F, Gil S, et al. Detection of the apoptosis suppressing oncoprotein bcl-2 in hormone refractory human prostate cancers. Am J Pathol 1993; 143: 390-400.
34. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene Bcl-s in the prostate and its association with the emergence of androgen-independent prostate cancer. Cancer Res 1992; 52: 6940-6944.
35. Hamdy FC, Olasimbo DJ, Rosario DJ, Silcocks PB, Fuller CE, Royds JA. bcl-2 oncoprotein expression in primary human prostatic adenocarcinoma. Proc 10th ESUOE Congr Urol Res 1993; 21: 450.
36. Gerdes J, Lemke H, Baisch H, Wacker HH, Scwab U, Stein H. Cell cycle analysis of a cell proliferation associated human nuclear antigen by the monoclonal antibody Ki-67. J Immunol 1984; 113: 1710-1715.